ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
121.07
-0.08 (-0.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close121.15
Open121.12
Bid116.00 x 1300
Ask121.69 x 800
Day's Range120.11 - 121.69
52 Week Range96.18 - 149.34
Volume875,376
Avg. Volume2,116,372
Market Cap26.938B
Beta1.06
PE Ratio (TTM)61.46
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Analyzing Alexion’s Cash Flows and Valuation Metrics
    Market Realist2 days ago

    Analyzing Alexion’s Cash Flows and Valuation Metrics

    Since the start of 2018, Alexion Pharmaceuticals (ALXN) has fallen -2.5% to close at $121 as of May 16. Alexion Pharmaceuticals generated $300 million from operating activities in the first quarter of 2018 compared to $308 million in the first quarter of 2017. In the first quarter of 2018, Alexion Pharmaceuticals used $254.7 million in investing activities compared to $495.3 million in the first quarter of 2017.

  • Market Realist2 days ago

    Exploring the Promising Research Pipeline of Alexion Therapeutics

    Alexion Pharmaceuticals (ALXN) is conducting two Phase 3 clinical studies in patients suffering from aHUS (atypical hemolytic uremic syndrome), which leads to life-threatening damage to the kidney, brain, heart, and other critical organs. This plan entails a once-per-week dosing to PNH (paroxysmal nocturnal hemoglobinuria) patients to support registration in PNH as well as aHUS.

  • Alexion Delivered a Solid Financial Performance in Q1 2018
    Market Realist2 days ago

    Alexion Delivered a Solid Financial Performance in Q1 2018

    Alexion Pharmaceuticals (ALXN) generated total revenue of $931 million in the first quarter of 2018 compared to $870 million in the first quarter of 2017. The increase in its sales resulted from an increase in its unit volumes due to increased global demand for Soliris and increased sales of Strensiq and Kanuma due to Alexion’s efforts to increase its patient outreach.

  • Market Realist2 days ago

    Analyzing Alexion’s Acquisition of Wilson Therapeutics

    Alexion Pharmaceuticals’ (ALXN) Kanuma is a recombinant form of the human LAL (lysosomal acid lipase) enzyme and is the only enzyme-replacement therapy approved by the FDA for the treatment of patients suffering from LAL deficiency (or LAL-D).

  • Insight into Alexion Pharmaceuticals’ Solid Product Performance
    Market Realist2 days ago

    Insight into Alexion Pharmaceuticals’ Solid Product Performance

    Alexion Pharmaceuticals’ (ALXN) major products include Soliris, Strensiq, and Kanuma. Soliris is a humanized monoclonal antibody targeted at treating inflammation associated with chronic disorders in several therapeutic areas, including hematology, nephrology, and neurology. Soliris has received approval for the treatment of PNH in the United States, Europe, Japan, and several other countries.

  • TheStreet.com6 days ago

    5 Stocks That Are Screaming Buys Right Now

    Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.

  • Recent Developments, Recommendations for JAZZ in May
    Market Realist10 days ago

    Recent Developments, Recommendations for JAZZ in May

    In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application (or sNDA) to the FDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric patients with narcolepsy. In April, Jazz Pharmaceuticals entered into an agreement with Spark Therapeutics (ONCE) whereby Jazz would purchase a rare pediatric disease priority review voucher for $110 million that would allow it to accelerate the FDA review process for one of its future regulatory submissions. Of the 23 analysts tracking Jazz Pharmaceuticals in May, six have recommended “strong buys” on the stock, while 13 have recommended “buys.” Four analysts have recommended “holds” on Jazz Pharmaceuticals in May.

  • How Did Jazz Pharmaceuticals Perform in 1Q18?
    Market Realist10 days ago

    How Did Jazz Pharmaceuticals Perform in 1Q18?

    In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Mass. had the fastest-growing economy in the Northeast for 2017
    American City Business Journals11 days ago

    Mass. had the fastest-growing economy in the Northeast for 2017

    Only 10 states nationwide grew their gross domestic product more quickly than Massachusetts did last year.

  • Benzinga14 days ago

    Benzinga's Insider Buys Of The Week: Alexion Pharmaceuticals, Sohu.com And More

    Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. A director of DDR Corp (NYSE: DDR) has been buying shares of this shopping center-focused real estate investment trust since February, including this past week's more than 1.9 million shares. Note that the latest purchases brought his stake to more than 55.47 million shares out of about 340 million shares outstanding.

  • Thomson Reuters StreetEvents18 days ago

    Edited Transcript of ALXN earnings conference call or presentation 26-Apr-18 2:00pm GMT

    Q1 2018 Alexion Pharmaceuticals Inc Earnings Call

  • Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1
    Zacks18 days ago

    Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

    The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool19 days ago

    3 Top Healthcare Stocks to Buy Right Now

    It could be the perfect time to add these healthcare stocks to your portfolio.

  • Analysts’ Recommendations for Vertex Pharmaceuticals
    Market Realist23 days ago

    Analysts’ Recommendations for Vertex Pharmaceuticals

    In February 2018, Vertex Pharmaceuticals (VRTX) announced the results of a Phase 2 trial for VX-150, an investigational NaV1.8 inhibitor. It had positive results in patients with acute pain after bunion removal and was well tolerated by patients.

  • How Did Vertex Pharmaceuticals Perform in 1Q18?
    Market Realist23 days ago

    How Did Vertex Pharmaceuticals Perform in 1Q18?

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) revenue rose ~33% YoY (year-over-year) to $638 million from $481 million. It grew ~3% quarter-over-quarter.

  • Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%
    Zacks23 days ago

    Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%

    Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

  • Alexion Saw 48% Rise in Diluted Earnings per Share in 1Q18
    Market Realist23 days ago

    Alexion Saw 48% Rise in Diluted Earnings per Share in 1Q18

    In 1Q18, Alexion Pharmaceuticals (ALXN) generated revenues of $930.9 million compared to $870 million in 1Q17, a ~7% increase on a year-over-year (or YoY) basis and a ~2% increase on a quarter-over-quarter basis. In the US, Europe, and Asia-Pacific, Alexion Pharmaceuticals generated revenues of $437.1 million, $270.7 million, and $92.2 million, respectively, compared to $360.1 million, $248.3 million, and $83.0 million in 1Q17.

  • Alexion Rockets As New Drug Proves Itself Against Blockbuster Soliris
    Investor's Business Daily24 days ago

    Alexion Rockets As New Drug Proves Itself Against Blockbuster Soliris

    Alexion Pharmaceuticals reported adjusted profit of $1.68 per share and $930.9 million in sales for its first quarter.

  • Why Domino's Pizza, Advanced Micro Devices, and Alexion Pharmaceuticals Jumped Today
    Motley Fool24 days ago

    Why Domino's Pizza, Advanced Micro Devices, and Alexion Pharmaceuticals Jumped Today

    Find out how these companies helped lift the overall market.

  • Here's Why Alexion Pharmaceuticals Is Surging Today
    Motley Fool24 days ago

    Here's Why Alexion Pharmaceuticals Is Surging Today

    Traders cheer an upbeat earnings report and positive clinical news. Here's what investors need to know.

  • Boston-bound Alexion gets $2.5B stock jolt as earnings, drug trial impress
    American City Business Journals24 days ago

    Boston-bound Alexion gets $2.5B stock jolt as earnings, drug trial impress

    When the company moves into its new headquarters in the Seaport District this summer, it will become the state’s third most valuable drugmaker.

  • Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
    Zacks24 days ago

    Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up

    Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.

  • Barrons.com24 days ago

    Drug Makers: A Dose of Robust Earnings

    With earnings season in full swing, pharma stocks got a boost today from AbbVie (ABBV), and Alexion Pharmaceuticals (ALXN), although Bristol-Myers Squibb (BMY) has given up its early gains. AbbVie said ...

  • Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates
    Zacks24 days ago

    Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates

    Alexion surpassed earnings and revenue expectations in the first quarter of 2018.